Eurofins Transplant Genomics Inc. (“ETG”) is a molecular diagnostics company committed to improving organ transplant outcomes with non-invasive serial monitoring guided by biomarkers. ETG’s product portfolio of both individual and combined whole blood gene expression and donor derived cell-free DNA testing is capable of reliably ruling out subclinical kidney rejection and acute rejection in kidney transplant patients. In addition to kidney transplantation testing, our newest product for liver transplant patients is a blood-based biomarker assay designed to rule out rejection as immunosuppression therapy is optimized. Basic Function and Scope of Responsibility:The Research and Development Director is primarily responsible for the leadership, development, optimization and validation of innovative methods in transplant diagnostics by utilizing technologies based on molecular, proteomic and/or bioinformatics approaches.